CVAC vs. SLN, PAHC, ORIC, LYEL, PHAR, BCYC, ZYME, NUVB, NRIX, and ANAB
Should you be buying CureVac stock or one of its competitors? The main competitors of CureVac include Silence Therapeutics (SLN), Phibro Animal Health (PAHC), ORIC Pharmaceuticals (ORIC), Lyell Immunopharma (LYEL), Pharming Group (PHAR), Bicycle Therapeutics (BCYC), Zymeworks (ZYME), Nuvation Bio (NUVB), Nurix Therapeutics (NRIX), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical preparations" industry.
Silence Therapeutics (NASDAQ:SLN) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.
Silence Therapeutics has a net margin of -171.41% compared to Silence Therapeutics' net margin of -483.85%. Silence Therapeutics' return on equity of -41.87% beat CureVac's return on equity.
Silence Therapeutics has higher earnings, but lower revenue than CureVac.
Silence Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, CureVac has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500.
CureVac received 1 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Silence Therapeutics an outperform vote while only 51.16% of users gave CureVac an outperform vote.
Silence Therapeutics presently has a consensus target price of $57.25, indicating a potential upside of 161.77%. CureVac has a consensus target price of $8.33, indicating a potential upside of 175.94%. Given Silence Therapeutics' higher probable upside, analysts clearly believe CureVac is more favorable than Silence Therapeutics.
In the previous week, CureVac had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 5 mentions for CureVac and 4 mentions for Silence Therapeutics. CureVac's average media sentiment score of 1.15 beat Silence Therapeutics' score of -0.03 indicating that Silence Therapeutics is being referred to more favorably in the media.
98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Silence Therapeutics beats CureVac on 9 of the 16 factors compared between the two stocks.
Get CureVac News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
